company background image
AMRX

Amneal Pharmaceuticals NYSE:AMRX Stock Report

Last Price

US$3.00

Market Cap

US$939.5m

7D

-2.9%

1Y

-37.1%

Updated

16 Aug, 2022

Data

Company Financials +
AMRX fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

AMRX Stock Overview

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas.

Rewards

Trading at 85.3% below our estimate of its fair value

Earnings are forecast to grow 70.85% per year

Risk Analysis

No risks detected for AMRX from our risk checks.

Amneal Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Amneal Pharmaceuticals
Historical stock prices
Current Share PriceUS$3.00
52 Week HighUS$5.99
52 Week LowUS$2.88
Beta1.21
1 Month Change-4.15%
3 Month Change-13.79%
1 Year Change-37.11%
3 Year Change8.30%
5 Year Changen/a
Change since IPO-80.01%

Recent News & Updates

Aug 04

Amneal Pharmaceuticals Q2 2022 Earnings Preview

Amneal Pharmaceuticals (NYSE:AMRX) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $0.19 (-24.0% Y/Y) and the consensus Revenue Estimate is $534.44M (-0.1% Y/Y). Over the last 2 years, AMRX has beaten EPS estimates 75% of the time and has beaten revenue estimates 63% of the time. Over the last 3 months, EPS estimates have seen 2 upward revisions and 5 downward. Revenue estimates have seen 0 upward revisions and 6 downward.

Shareholder Returns

AMRXUS PharmaceuticalsUS Market
7D-2.9%0.3%4.5%
1Y-37.1%-0.9%-8.9%

Return vs Industry: AMRX underperformed the US Pharmaceuticals industry which returned 0.3% over the past year.

Return vs Market: AMRX underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is AMRX's price volatile compared to industry and market?
AMRX volatility
AMRX Average Weekly Movement8.9%
Pharmaceuticals Industry Average Movement12.1%
Market Average Movement7.6%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: AMRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: AMRX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20027,000Chirag Patelhttps://www.amneal.com

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Amneal Pharmaceuticals Fundamentals Summary

How do Amneal Pharmaceuticals's earnings and revenue compare to its market cap?
AMRX fundamental statistics
Market CapUS$939.48m
Earnings (TTM)-US$133.58m
Revenue (TTM)US$2.12b

0.2x

P/S Ratio

-3.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AMRX income statement (TTM)
RevenueUS$2.12b
Cost of RevenueUS$1.36b
Gross ProfitUS$763.45m
Other ExpensesUS$897.03m
Earnings-US$133.58m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.88
Gross Margin35.97%
Net Profit Margin-6.29%
Debt/Equity Ratio1,454.5%

How did AMRX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is AMRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AMRX?

Other financial metrics that can be useful for relative valuation.

AMRX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.5x
Enterprise Value/EBITDA7.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does AMRX's PS Ratio compare to its peers?

AMRX PS Ratio vs Peers
The above table shows the PS ratio for AMRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.6x
INVA Innoviva
2.5x-41.4%US$1.0b
PROC Procaps Group
2.1x11.8%US$880.0m
PAHC Phibro Animal Health
0.8x4.1%US$759.4m
NKTR Nektar Therapeutics
9.1x7.2%US$877.1m
AMRX Amneal Pharmaceuticals
0.2x3.5%US$939.5m

Price-To-Sales vs Peers: AMRX is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (3.6x).


Price to Earnings Ratio vs Industry

How does AMRX's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: AMRX is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Pharmaceuticals industry average (3.9x)


Price to Sales Ratio vs Fair Ratio

What is AMRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AMRX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ratio2.2x

Price-To-Sales vs Fair Ratio: AMRX is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (2.2x).


Share Price vs Fair Value

What is the Fair Price of AMRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AMRX ($3) is trading below our estimate of fair value ($20.42)

Significantly Below Fair Value: AMRX is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Amneal Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


70.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: AMRX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AMRX is expected to become profitable in the next 3 years.

Revenue vs Market: AMRX's revenue (3.5% per year) is forecast to grow slower than the US market (7.9% per year).

High Growth Revenue: AMRX's revenue (3.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AMRX's Return on Equity is forecast to be very high in 3 years time (43.9%).


Discover growth companies

Past Performance

How has Amneal Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-25.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AMRX is currently unprofitable.

Growing Profit Margin: AMRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AMRX is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.

Accelerating Growth: Unable to compare AMRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AMRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).


Return on Equity

High ROE: AMRX has a negative Return on Equity (-143.07%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Amneal Pharmaceuticals's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AMRX's short term assets ($1.6B) exceed its short term liabilities ($993.1M).

Long Term Liabilities: AMRX's short term assets ($1.6B) do not cover its long term liabilities ($2.9B).


Debt to Equity History and Analysis

Debt Level: AMRX's net debt to equity ratio (1405.4%) is considered high.

Reducing Debt: AMRX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable AMRX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: AMRX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 28.2% per year.


Discover healthy companies

Dividend

What is Amneal Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AMRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AMRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AMRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AMRX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: AMRX is not paying a notable dividend for the US market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AMRX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Chirag Patel (55 yo)

17.58yrs

Tenure

US$4,785,116

Compensation

Mr. Chirag K. Patel has been Co-Chief Executive Officer, President and Director of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as D...


CEO Compensation Analysis

Compensation vs Market: Chirag's total compensation ($USD4.79M) is about average for companies of similar size in the US market ($USD3.83M).

Compensation vs Earnings: Chirag's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AMRX's management team is considered experienced (4 years average tenure).


Board Members

Experienced Board: AMRX's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Amneal Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Amneal Pharmaceuticals, Inc.
  • Ticker: AMRX
  • Exchange: NYSE
  • Founded: 2002
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$939.478m
  • Market Cap: US$454.226m
  • Shares outstanding: 303.53m
  • Website: https://www.amneal.com

Number of Employees


Location

  • Amneal Pharmaceuticals, Inc.
  • 400 Crossing Boulevard
  • 3rd Floor
  • Bridgewater
  • New Jersey
  • 8807
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/16 00:00
End of Day Share Price2022/08/16 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.